Potential benefits of prasugrel and ticagrelor is diabetics are not substantiated by the Food and Drug Administration adverse event repository-Reference-Cited by-同舟云学术

Potential benefits of prasugrel and ticagrelor is diabetics are not substantiated by the Food and Drug Administration adverse event repository

Published:2018-02-14 Issue:3 Volume:4 Page:142-143
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Serebruany Victor L¹,Kim Moo Hyun²,Lomakin Nikita³

Affiliation:

1. Department of Neurology, Johns Hopkins University, Baltimore, Stroke Unit, 14110 Rover Mill Road, West Friendship, Maryland, 21794 USA

2. Department of Cardiology, Dong-A University, 26 Daesingongwon-Ro Seo-Gu, Busan 602-812, South Korea

3. Central Clinical Hospital of the Administrative Affairs of the President of the Russian Federation, Intensive Cardiology Department, Marshala Timoshenko Ulitsa, 15, Moscow, 121359, Russia

Funder

Korea Health Industry Development Institute

KHIDI

Ministry of Education

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/article-pdf/4/3/142/25034914/pvy006.pdf

Reference10 articles.

1. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion;Zannad;Eur Heart J Cardiovasc Pharmacother,2016

2. . Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes;Lettino;Eur Heart J Cardiovasc Pharmacother,2017

3. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38;Wiviott;Circulation,2008

4. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial;James;Eur Heart J,2010

5. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials;Gargiulo;BMJ,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System;European Heart Journal - Cardiovascular Pharmacotherapy;2018-09-06